Download PDF
Aktuelle Neurologie 2017; 44(01): 19-26
DOI: 10.1055/s-0042-123500
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Übergreifende Konzepte der Neurodegeneration

Overlapping Concepts of Neurodegeneration
Jos Steffen Becktepe
1   Klinik für Neurologie, Campus Kiel, Universitätsklinikum Schleswig Holstein, Christian Albrechts Universität Kiel
,
Felix Gövert
1   Klinik für Neurologie, Campus Kiel, Universitätsklinikum Schleswig Holstein, Christian Albrechts Universität Kiel
,
Günther Deuschl
1   Klinik für Neurologie, Campus Kiel, Universitätsklinikum Schleswig Holstein, Christian Albrechts Universität Kiel
› Author Affiliations
Further Information

Publication History

Publication Date:
01 February 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Nach jahrzehntelanger Suche nach den molekularen Grundlagen der Neurodegeneration, die zahllose mögliche aber dann wieder verworfene oder als Epiphänomene eingeordnete Mechanismen aufgedeckt haben, kristallisiert sich ein möglicherweise gemeinsames und übergreifendes Konzept der Ausbreitung neurodegenerativer Erkrankungen heraus. Dieses Prinzip der prionartigen Ausbreitung der Synucleinopathien, Tauopathien und β-Amyloiderkrankungen wird hier dargestellt. Dieses Konzept ist noch nicht ausgereift und ausreichend belegt, aber es ist wert auch von Klinikern zur Kenntnis genommen zu werden. Neue Wege der Therapieforschung können damit eingeschlagen werden.

Abstract

Over many years of extensive research on the molecular principles of neurodegeneration, numerous different hypotheses were suggested and rejected; now a common and overlapping concept of neurodegeneration appears to have crytallised. This is the concept of prion-like spreading in alpha-synucleinopathies, tauopathies and beta-amyloid diseases and is highlighted in this review. Despite the concept being far from being proven, clinicians should take notice of these developments. This new hypothesis may encourage new therapeutic approaches for neurodegenerative disorders.

Schlüsselwörter

Neurodegeneration - prionartige Erkrankungen - Synucleinopathien - Tauopathien

Keywords

prion-like disease - neurodegeneration - synucleinopathy - tauopathy
 

  • Literatur

  • 1 Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013; 501: 45-51
    CrossrefPubMedGoogle Scholar
  • 2 Forloni G, Artuso V, La Vitola P. et al. Oligomeropathies and pathogenesis of Alzheimer and Parkinson‘s diseases. Mov Disord 2016; 31: 771-781
    CrossrefPubMedGoogle Scholar
  • 3 Witt K, Deuschl G, Bartsch T. Frontotemporal dementias. Der Nervenarzt 2013; 84: 20-32
    CrossrefPubMedGoogle Scholar
  • 4 Mayo MC, Bordelon Y. Dementia with Lewy bodies. Seminars in neurology 2014; 34: 182-188
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Thal DR, Rub U, Orantes M. et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800
    CrossrefPubMedGoogle Scholar
  • 6 Braak H, Del Tredici K, Rub U. et al. Staging of brain pathology related to sporadic Parkinson‘s disease. Neurobiol Aging 2003; 24: 197-211
    CrossrefPubMedGoogle Scholar
  • 7 Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259
    CrossrefPubMedGoogle Scholar
  • 8 Goedert M. Neurodegeneration. Alzheimer‘s and Parkinson‘s diseases: The prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science 2015; 349: 1255555
    CrossrefPubMedGoogle Scholar
  • 9 Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998; 95: 13363-13383
    CrossrefPubMedGoogle Scholar
  • 10 Aguzzi A, Lakkaraju AK. Cell Biology of Prions and Prionoids: A Status Report. Trends Cell Biol 2016; 26: 40-51
    CrossrefPubMedGoogle Scholar
  • 11 Vilchez D, Saez I, Dillin A. The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat Commun 2014; 5: 5659
    CrossrefPubMedGoogle Scholar
  • 12 Wadsworth JD, Collinge J. Molecular pathology of human prion disease. Acta neuropathologica 2011; 121: 69-77
    CrossrefPubMedGoogle Scholar
  • 13 Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science 2007; 318: 930-936
    CrossrefPubMedGoogle Scholar
  • 14 Kahle PJ, Neumann M, Ozmen L. et al. Subcellular localization of wild-type and Parkinson‘s disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci 2000; 20: 6365-6373
    CrossrefPubMedGoogle Scholar
  • 15 Singleton AB, Farrer M, Johnson J. et al. alpha-Synuclein locus triplication causes Parkinson‘s disease. Science 2003; 302: 841
    CrossrefPubMedGoogle Scholar
  • 16 Hardy J. Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: ‘permissive templating’ as a general mechanism underlying neurodegeneration. Biochem Soc Trans 2005; 33: 578-581
    CrossrefPubMedGoogle Scholar
  • 17 Li JY, Englund E, Holton JL. et al. Lewy bodies in grafted neurons in subjects with Parkinson‘s disease suggest host-to-graft disease propagation. Nat Med 2008; 14: 501-503
    CrossrefPubMedGoogle Scholar
  • 18 Kordower JH, Chu Y, Hauser RA. et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson‘s disease. Nat Med 2008; 14: 504-506
    CrossrefPubMedGoogle Scholar
  • 19 Chu Y, Kordower JH. Lewy body pathology in fetal grafts. Ann N Y Acad Sci 2010; 1184: 55-67
    CrossrefPubMedGoogle Scholar
  • 20 Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005; 25: 6016-6024
    CrossrefPubMedGoogle Scholar
  • 21 Volpicelli-Daley LA, Luk KC, Patel TP. et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72: 57-71
    CrossrefPubMedGoogle Scholar
  • 22 Luk KC, Song C, O‘Brien P. et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 2009; 106: 20051-20056
    CrossrefPubMedGoogle Scholar
  • 23 Angot E, Steiner JA, Lema Tome CM. et al. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One 2012; 7: e39465
    CrossrefPubMedGoogle Scholar
  • 24 Mougenot AL, Nicot S, Bencsik A. et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 2012; 33: 2225-2228
    CrossrefPubMedGoogle Scholar
  • 25 Recasens A, Dehay B, Bove J. et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014; 75: 351-362
    CrossrefPubMedGoogle Scholar
  • 26 Paumier KL, Luk KC, Manfredsson FP. et al. Intrastriatal injection of pre-formed mouse alpha-synuclein fibrils into rats triggers alpha-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol Dis 2015; 82: 185-199
    CrossrefPubMedGoogle Scholar
  • 27 Prusiner SB, Woerman AL, Mordes DA. et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A 2015; 112: E5308-E5317
    CrossrefPubMedGoogle Scholar
  • 28 Peelaerts W, Bousset L, Van der Perren A. et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015; 522: 340-344
    CrossrefPubMedGoogle Scholar
  • 29 Melki R. Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases. J Parkinsons Dis 2015; 5: 217-227
    PubMedGoogle Scholar
  • 30 Del Tredici K, Braak H. Review: Sporadic Parkinson‘s disease: development and distribution of alpha-synuclein pathology. Neuropathol Appl Neurobiol 2016; 42: 33-50
    CrossrefPubMedGoogle Scholar
  • 31 Bruni AC, Conidi ME, Bernardi L. Genetics in degenerative dementia: current status and applicability. Alzheimer Dis Assoc Disord 2014; 28: 199-205
    CrossrefPubMedGoogle Scholar
  • 32 Ridley RM, Baker HF, Windle CP. et al. Very long term studies of the seeding of beta-amyloidosis in primates. J Neural Transm (Vienna) 2006; 113: 1243-1251
    CrossrefPubMedGoogle Scholar
  • 33 Meyer-Luehmann M, Coomaraswamy J, Bolmont T. et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006; 313: 1781-1784
    CrossrefPubMedGoogle Scholar
  • 34 Eisele YS, Obermuller U, Heilbronner G. et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010; 330: 980-982
    CrossrefPubMedGoogle Scholar
  • 35 Eisele YS, Bolmont T, Heikenwalder M. et al. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A 2009; 106: 12926-12931
    CrossrefPubMedGoogle Scholar
  • 36 Morales R, Duran-Aniotz C, Castilla J. et al. De novo induction of amyloid-beta deposition in vivo. Mol Psychiatry 2012; 17: 1347-1353
    CrossrefPubMedGoogle Scholar
  • 37 Stohr J, Condello C, Watts JC. et al. Distinct synthetic Abeta prion strains producing different amyloid deposits in bigenic mice. Proc Natl Acad Sci U S A 2014; 111: 10329-10334
    CrossrefPubMedGoogle Scholar
  • 38 Cohen ML, Kim C, Haldiman T. et al. Rapidly progressive Alzheimer‘s disease features distinct structures of amyloid-beta. Brain 2015; 138: 1009-1022
    CrossrefPubMedGoogle Scholar
  • 39 Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121-1159
    CrossrefPubMedGoogle Scholar
  • 40 Walker LC, Jucker M. Neurodegenerative diseases: expanding the prion concept. Annu Rev Neurosci 2015; 38: 87-103
    CrossrefPubMedGoogle Scholar
  • 41 Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and alpha-synuclein in neurodegeneration. Brain 2017; 140: 266-278
    CrossrefPubMedGoogle Scholar
  • 42 Nonaka T, Watanabe ST, Iwatsubo T. et al. Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. J Biol Chem 2010; 285: 34885-34898
    CrossrefPubMedGoogle Scholar
  • 43 Falcon B, Cavallini A, Angers R. et al. Conformation determines the seeding potencies of native and recombinant Tau aggregates. J Biol Chem 2015; 290: 1049-1065
    CrossrefPubMedGoogle Scholar
  • 44 Clavaguera F, Bolmont T, Crowther RA. et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11: 909-913
    CrossrefPubMedGoogle Scholar
  • 45 de Calignon A, Polydoro M, Suarez-Calvet M. et al. Propagation of tau pathology in a model of early Alzheimer‘s disease. Neuron 2012; 73: 685-697
    CrossrefPubMedGoogle Scholar
  • 46 Clavaguera F, Akatsu H, Fraser G. et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A 2013; 110: 9535-9540
    CrossrefPubMedGoogle Scholar
  • 47 Saito Y, Ruberu NN, Sawabe M. et al. Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol 2004; 63: 911-918
    CrossrefPubMedGoogle Scholar
  • 48 Grad LI, Fernando SM, Cashman NR. From molecule to molecule and cell to cell: prion-like mechanisms in amyotrophic lateral sclerosis. Neurobiol Dis 2015; 77: 257-265
    CrossrefPubMedGoogle Scholar
  • 49 Synofzik M, Ronchi D, Keskin I. et al. Mutant superoxide dismutase-1 indistinguishable from wild-type causes ALS. Hum Mol Genet 2012; 21: 3568-3574
    CrossrefPubMedGoogle Scholar
  • 50 Gurney ME, Pu H, Chiu AY. et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775
    CrossrefPubMedGoogle Scholar
  • 51 Bendotti C, Marino M, Cheroni C. et al. Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response. Prog Neurobiol 2012; 97: 101-126
    CrossrefPubMedGoogle Scholar
  • 52 Grad LI, Guest WC, Yanai A. et al. Intermolecular transmission of superoxide dismutase 1 misfolding in living cells. Proc Natl Acad Sci U S A 2011; 108: 16398-16403
    CrossrefPubMedGoogle Scholar
  • 53 Graffmo KS, Forsberg K, Bergh J. et al. Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis. Hum Mol Genet 2013; 22: 51-60
    CrossrefPubMedGoogle Scholar
  • 54 Ayers JI, Fromholt S, Koch M. et al. Experimental transmissibility of mutant SOD1 motor neuron disease. Acta Neuropathol 2014; 128: 791-803
    CrossrefPubMedGoogle Scholar
  • 55 Neumann M, Sampathu DM, Kwong LK. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130-133
    CrossrefPubMedGoogle Scholar
  • 56 Lee S, Kim HJ. Prion-like mechanism in amyotrophic lateral sclerosis: are protein aggregates the key?. Exp Neurobiol 2015; 24: 1-7
    CrossrefPubMedGoogle Scholar
  • 57 Feiler MS, Strobel B, Freischmidt A. et al. TDP-43 is intercellularly transmitted across axon terminals. J Cell Biol 2015; 211: 897-911
    CrossrefPubMedGoogle Scholar
  • 58 Braak H, Brettschneider J, Ludolph AC. et al. Amyotrophic lateral sclerosis–a model of corticofugal axonal spread. Nat Rev Neurol 2013; 9: 708-714
    CrossrefPubMedGoogle Scholar
  • 59 Jaunmuktane Z, Mead S, Ellis M. et al. Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature 2015; 525: 247-250
    CrossrefPubMedGoogle Scholar
  • 60 Frontzek K, Lutz MI, Aguzzi A. et al. Amyloid-beta pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt-Jakob disease after dural grafting. Swiss Med Wkly 2016; 146: w14287
    PubMedGoogle Scholar
  • 61 Sevigny J, Chiao P, Bussiere T. et al. The antibody aducanumab reduces Abeta plaques in Alzheimer‘s disease. Nature 2016; 537: 50-56
    CrossrefPubMedGoogle Scholar